← MYLAN (VTRS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MYLAN (VTRS)
Pharmaceutical Preparations · market cap $19.7B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-17
NDA Filing
Pipeline
20
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Viatris Inc. (VTRS) is a global generics and branded pharmaceutical company formed in 2020 via the merger of Mylan and Upjohn (Pfizer's legacy off-patent brands division), headquartered in Canonsburg, PA, with ~32,000 employees and an $18.9B market cap. The company carries a substantial $12.5B net debt load against $1.8B cash, with revenues declining from $17.9B in 2021 to $14.3B in 2025 and a $3.5B net loss in 2025. Near-term catalysts center on an NDA filing in October 2026 and two Phase 3 readouts for transdermal progestin contraceptive systems in early-to-mid 2027.
The catalyst path
- 2026-10-17NDA Filingimp 7/10
- 2026-11-05 (est.)Earningsimp 5/10
- 2026-11-30 (est.)Phase 2 · MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)imp 7/10
- 2026-12-31Phase 3imp 8/10
- 2027-03-15 (est.)Phase 3 · Transdermal system containing progestinimp 9/10
- 2027-05-15 (est.)Phase 3 · Transdermal system containing progestinimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Amlodipine/atorvastatin single pill | Phase 3 | Hypertension |
| MYL-1601D Product | Phase 3 | Diabetes Mellitus, Type 1 |
| venlafaxine ER 75 mg/day (fixed dose) | Phase 3 | Major Depressive Disorder |
| LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION | Phase 3 | Glaucoma, Primary Open Angle (POAG) |
| Revefenacin | Phase 3 | Chronic Obstructive Pulmonary Disease, COPD |
| Econazole Nitrate Cream, 1% | Phase 3 | Tinea Pedis |
| Eletriptan 20 mg | Phase 3 | Migraine With or Without Aura |
| Eletriptan 80 mg | Phase 3 | Migraine With or Without Aura |
| TD-4208 700 μg | Phase 2 | Chronic Obstructive Pulmonary Disease, COPD |
| MR-107A-01 | Phase 2 | Pain |
| pramipexole | Phase 3 | Restless Legs Syndrome |
| Diclofenac sodium gel 1% | Phase 3 | Osteoarthritis, Knee |
| tolterodine extended release capsule | Phase 3 | Urinary Incontinence |
| MR-130A-01 Transdermal patch | Phase 2 | Contraception |
| MR-107A-02 | Phase 3 | Acute Pain |
| Venlafaxine ER | Phase 3 | Major Depressive Disorder |
| Venlafaxine XR | Phase 3 | Anxiety |
| Xalacom | Phase 3 | Glaucoma, Open Angle |
| Mylan's insulin glargine | Phase 3 | Type 1 Diabetes |
| Lantus® | Phase 3 | Type 2 Diabetes |
Price & technical context
3-month
+4.6%
6-month
+28.1%
12-month
+76.4%
52-wk range
$9.74–$18.27
vs 50-day MA
+3.1%
vs 200-day MA
+14.2%
Realized vol
31.6%
Max drawdown
-45.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VTRS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.